Open Label Randomized Bioequivalence Study to Evaluate the PK and Safety Profile of Bevacizumab Biosimilar (BEVZ92) With FOLFOX or FOLFIRI vs Bevacizumab (AVASTIN) With FOLFOX or FOLFIRI in First-line Treatment for mCRC Patients.

Trial Profile

Open Label Randomized Bioequivalence Study to Evaluate the PK and Safety Profile of Bevacizumab Biosimilar (BEVZ92) With FOLFOX or FOLFIRI vs Bevacizumab (AVASTIN) With FOLFOX or FOLFIRI in First-line Treatment for mCRC Patients.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Colorectal cancer
  • Focus Pharmacokinetics
  • Sponsors mAbxience
  • Most Recent Events

    • 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 22 Dec 2016 Planned End Date changed from 1 Sep 2016 to 1 Jun 2017.
    • 22 Dec 2016 Status changed from completed to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top